Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus

Seitaro Omoto,1 Takehito Taniura,2 Tohru Nishizawa,3 Takeshi Tamaki,3 Akira Shouzu,4 Shosaku Nomura3 1Division of Internal Medicine, Korigaoka Yukeikai Hospital, 2Division of Internal Medicine, Daiwa Hospital, 3First Department of Internal Medicine, Kansai Medical University, 4Division of Internal M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Omoto S, Taniura T, Nishizawa T, Tamaki T, Shouzu A,Nomura S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/5985824997e146b1b27fe4ccff80972e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5985824997e146b1b27fe4ccff80972e
record_format	dspace
spelling	oai:doaj.org-article:5985824997e146b1b27fe4ccff80972e2021-12-02T01:03:00ZAnti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus1178-7007https://doaj.org/article/5985824997e146b1b27fe4ccff80972e2015-07-01T00:00:00Zhttp://www.dovepress.com/anti-atherosclerotic-effects-of-sitagliptin-in-patients-with-type-2-di-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Seitaro Omoto,1 Takehito Taniura,2 Tohru Nishizawa,3 Takeshi Tamaki,3 Akira Shouzu,4 Shosaku Nomura3 1Division of Internal Medicine, Korigaoka Yukeikai Hospital, 2Division of Internal Medicine, Daiwa Hospital, 3First Department of Internal Medicine, Kansai Medical University, 4Division of Internal Medicine, Saiseikai Izuo Hospital, Osaka, Japan Background: Advanced glycation end products, selectins, and adiponectin play important roles in the development of atherosclerosis in individuals with diabetes. Sitagliptin has been shown to reduce the concentration of glycated hemoglobin in diabetic patients. However, its effects on soluble receptor for advanced glycation end products (sRAGEs), selectins, and adiponectin in these patients are poorly understood. This study was conducted to assess the effects of sitagliptin on the circulating levels of sRAGEs, monocyte chemoattractant protein-1 (MCP-1), selectins, and adiponectin in patients with type 2 diabetes. Methods: Diabetic patients eligible for sitagliptin monotherapy or combination therapy (eg, sitagliptin plus a sulfonylurea) were administered sitagliptin (50 mg/day) for 6 months. Levels of soluble P-selectin (sP-selectin), soluble E-selectin (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1), MCP-1, sRAGEs, and adiponectin were measured by ELISA at baseline and after 3 and 6 months of treatment. Results: At baseline, the levels of MCP-1, sP-selectin, sE-selectin, and sVCAM-1 were higher and the level of adiponectin was lower in diabetic patients than in nondiabetic patients. Sitagliptin therapy for 3 and 6 months significantly reduced plasma levels of sP-selectin, sE-selectin, sVCAM-1, and MCP-1 relative to baseline, while significantly increasing adiponectin levels. sRAGEs did not exhibit a statistical significance, although there was an increasing tendency. Furthermore, the reductions in sP-selectin, sE-selectin, sVCAM-1, and MCP-1 during sitagliptin therapy were significantly greater in responders, defined as patients with a significant increase in adiponectin levels, than in nonresponders. In contrast, responders showed a significant increase in the plasma concentration of sRAGEs. Conclusion: Sitagliptin shows an adiponectin-dependent anti-atherothrombotic effect, which may be beneficial for primary prevention of atherothrombosis, in patients with type 2 diabetes. Keywords: type 2 diabetes mellitus, sitagliptin, sRAGE, selectins, sVCAM-1, adiponectinOmoto STaniura TNishizawa TTamaki TShouzu A,Nomura SDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 339-345 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Omoto S Taniura T Nishizawa T Tamaki T Shouzu A,Nomura S Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
description	Seitaro Omoto,1 Takehito Taniura,2 Tohru Nishizawa,3 Takeshi Tamaki,3 Akira Shouzu,4 Shosaku Nomura3 1Division of Internal Medicine, Korigaoka Yukeikai Hospital, 2Division of Internal Medicine, Daiwa Hospital, 3First Department of Internal Medicine, Kansai Medical University, 4Division of Internal Medicine, Saiseikai Izuo Hospital, Osaka, Japan Background: Advanced glycation end products, selectins, and adiponectin play important roles in the development of atherosclerosis in individuals with diabetes. Sitagliptin has been shown to reduce the concentration of glycated hemoglobin in diabetic patients. However, its effects on soluble receptor for advanced glycation end products (sRAGEs), selectins, and adiponectin in these patients are poorly understood. This study was conducted to assess the effects of sitagliptin on the circulating levels of sRAGEs, monocyte chemoattractant protein-1 (MCP-1), selectins, and adiponectin in patients with type 2 diabetes. Methods: Diabetic patients eligible for sitagliptin monotherapy or combination therapy (eg, sitagliptin plus a sulfonylurea) were administered sitagliptin (50 mg/day) for 6 months. Levels of soluble P-selectin (sP-selectin), soluble E-selectin (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1), MCP-1, sRAGEs, and adiponectin were measured by ELISA at baseline and after 3 and 6 months of treatment. Results: At baseline, the levels of MCP-1, sP-selectin, sE-selectin, and sVCAM-1 were higher and the level of adiponectin was lower in diabetic patients than in nondiabetic patients. Sitagliptin therapy for 3 and 6 months significantly reduced plasma levels of sP-selectin, sE-selectin, sVCAM-1, and MCP-1 relative to baseline, while significantly increasing adiponectin levels. sRAGEs did not exhibit a statistical significance, although there was an increasing tendency. Furthermore, the reductions in sP-selectin, sE-selectin, sVCAM-1, and MCP-1 during sitagliptin therapy were significantly greater in responders, defined as patients with a significant increase in adiponectin levels, than in nonresponders. In contrast, responders showed a significant increase in the plasma concentration of sRAGEs. Conclusion: Sitagliptin shows an adiponectin-dependent anti-atherothrombotic effect, which may be beneficial for primary prevention of atherothrombosis, in patients with type 2 diabetes. Keywords: type 2 diabetes mellitus, sitagliptin, sRAGE, selectins, sVCAM-1, adiponectin
format	article
author	Omoto S Taniura T Nishizawa T Tamaki T Shouzu A,Nomura S
author_facet	Omoto S Taniura T Nishizawa T Tamaki T Shouzu A,Nomura S
author_sort	Omoto S
title	Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
title_short	Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
title_full	Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
title_fullStr	Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
title_full_unstemmed	Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
title_sort	anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/5985824997e146b1b27fe4ccff80972e
work_keys_str_mv	AT omotos antiatheroscleroticeffectsofsitagliptininpatientswithtype2diabetesmellitus AT taniurat antiatheroscleroticeffectsofsitagliptininpatientswithtype2diabetesmellitus AT nishizawat antiatheroscleroticeffectsofsitagliptininpatientswithtype2diabetesmellitus AT tamakit antiatheroscleroticeffectsofsitagliptininpatientswithtype2diabetesmellitus AT shouzuanomuras antiatheroscleroticeffectsofsitagliptininpatientswithtype2diabetesmellitus
_version_	1718403317663531008

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus

Ejemplares similares